Foghorn Therapeutics vs Prelude Therapeutics
FHTX and PRLD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FHTX and PRLD compare
Prelude Therapeutics is the larger company, worth 2.4 times as much as Foghorn Therapeutics ($302M against $124M).
Foghorn Therapeutics grew revenue faster over the last twelve months (357% versus 220% for Prelude Therapeutics).
Foghorn Therapeutics keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −270% at Prelude Therapeutics.
Foghorn Therapeutics scores higher on the StockData Score (10 against 8 for Prelude Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FHTX | PRLD |
|---|---|---|
| Size and price | ||
| Market cap | $124M | $302M |
| Share price | $2.09 | $3.78 |
| Change, 1 year | −52.7% | 200% |
| Change, 5 years | −84.7% | −73.9% |
| Beta (5Y) | 1.87 | 1.24 |
| Employees | 106 | 79 |
| StockData Score | ||
| Total score | 10 (better) | 8 |
| Valuation score | 1 | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 29.9× | – |
| P/S | 1.1× (better) | 13.5× |
| P/B | – | 2.3× |
| EV/EBITDA | 11.5× | – |
| FCF yield | −67.4% | −11.0% (better) |
| Fair value | $2.08 | $2.16 |
| Margin of safety | −0.44% (better) | −74.8% |
| Growth | ||
| Revenue growth (TTM) | 357% (better) | 220% |
| Revenue growth, 5Y average | 135% | – |
| Profitability | ||
| Operating margin | 2.1% (better) | −301% |
| Net margin | 8.4% (better) | −270% |
| FCF margin | −74.6% (better) | −148% |
| Return on equity | – | −57.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 4.24 (better) | 4.07 |
| Altman Z-score | −2.66 | −2.29 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 75.6% | 62.2% |
| Held by insiders | 36.3% | 40.5% |
| Insider net buying, 12 months | – | $25.0M |
| Short interest, % of float | 6.0% | 8.8% |
Go deeper
- FHTX stock overview
- FHTX income statement
- FHTX valuation and score
- PRLD stock overview
- PRLD income statement
- PRLD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.